학술논문
Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis
Document Type
article
Author
Shobana Anpalakhan; Alessio Signori; Alessio Cortellini; Elena Verzoni; Raffaele Giusti; Giuseppe Aprile; Paola Ermacora; Annamaria Catino; Stefania Pipitone; Marilena Di Napoli; Vieri Scotti; Francesca Mazzoni; Pamela F. Guglielmini; Antonello Veccia; Marco Maruzzo; Giovanni Schinzari; Chiara Casadei; Francesco Grossi; Mimma Rizzo; Vincenzo Montesarchio; Francesco Verderame; Manlio Mencoboni; Fable Zustovich; Lucia Fratino; Caterina Accettura; Saverio Cinieri; Carlo Alberto Tondini; Andrea Camerini; Maria Chiara Banzi; Mariella Sorarù; Paolo Andrea Zucali; Francesca Vignani; Serena Ricciardi; Antonio Russo; Agnese Cosenza; Massimo Di Maio; Ugo De Giorgi; Sandro Pignata; Diana Giannarelli; Carmine Pinto; Sebastiano Buti; Giuseppe Fornarini; Sara Elena Rebuzzi; Pasquale Rescigno; Alfredo Addeo; Giuseppe L. Banna; Melissa Bersanelli
Source
iScience, Vol 26, Iss 11, Pp 107970- (2023)
Subject
Language
English
ISSN
2589-0042
Abstract
Summary: The neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammatory index (SII) have been reported as prognosticators in non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and melanoma. This analysis of the INVIDIa-2 study on influenza vaccination in patients with cancer treated with immune checkpoint inhibitors (ICIs) assessed NLR and SII on overall survival (OS) by literature-reported (LR), receiver operating characteristic curve (ROC)-derived (ROC) cutoffs or as continuous variable (CV). NLR and SII with ROC cutoffs of